Search

Your search keyword '"Guida Cesare"' showing total 45 results
Start Over Author "Guida Cesare"
45 results on '"Guida Cesare"'

1. Adjuvant modern radiotherapy in resected pN2 NSCLC patients: results from a multicentre retrospective analysis on acute and late toxicity on behalf of AIRO thoracic oncology study group: the RAC-TAC study

Author

Nardone, Valerio, Bruni, Alessio, Franceschini, Davide, Marini, Beatrice, Vagge, Stefano, Ciammella, Patrizia, Sepulcri, Matteo, Cappelli, Anna, D’Angelo, Elisa, De Marco, Giuseppina, Angrisani, Antonio, Manetta, Mattia, Scricciolo, Melissa, Guida, Cesare, Aiello, Dario, Borghetti, Paolo, and Cappabianca, Salvatore

Published
2024
Full Text
View/download PDF

2. Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor®)

Author

Franco Rossella, Calvanese MariaGrazia, Murino Paola, Manzo Roberto, Guida Cesare, Gennaro Davide, Anania Caterina, and Ravo Vincenzo

Subjects
Radiotherapy, Breast, Toxicity, Skin, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Introduction This is an observational study and the aim is to evaluate the effect of dietary supplements based on Resveratrol, Lycopene, Vitamin C and Anthocyanins (Ixor®) in reducing skin toxicity due to external beam radiotherapy in patients affected by breast cancer. Materials and methods 71 patients were enrolled and they were divided in two different groups: a control group (CG) of 41 patients treated with prophylactic topical therapy based on hyaluronic acid and topical steroid therapy in case of occurrence of radiodermatitis, and a Ixor-Group (IG) of 30 patients treated also with an oral therapy based on Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor®) at a dose of 2 tablets/day, starting from 10 days before the radiation treatment until 10 days after the end of treatment. Skin toxicity has been related to PTV, to breast volume that received a radiation dose equal or lower than 107%, included between 107% and 110%, or greater than 110% of the prescribed dose. Moreover it's been studied the relationship between skin toxicity and the chemotherapy schedule used before treatment. We calculated in both groups the percentage of patients who had a skin toxicity of grade 2 or 3 (according to RTOG scale). Absolute risk reduction (ARR), relative risk (RR) and odds ratio (OR) have been calculated for each relationship. Results Control Group (CG) patients with a PTV > 500 ml presented skin toxicity G2 + G3 in 30% of cases, versus 25% of Ixor-Group (IG) [OR 0.77]. In patients with a PTV < 500 ml G2 + G3 toxicity was 0% in the IG compared to 18% in CG (OR 0.23). When Dmax was less than or equal to 107% of the prescribed dose skin toxicity was G2 + G3 in 12.5% in CG, versus 0% in IG (OR 0.73), instead when Dmax was included between 107 and 110% of the prescribed dose, G2 + G3 skin toxicity was 35% in CG and 21% in IG (OR 0.50). In patients undergoing chemotherapy with anthracyclines and taxanes, G2 + G3 toxicity was 27% in CG, against 20% in IG (OR 0.68). Conclusions The protective effect of Resveratrol, Lycopene, Vitamin C and Anthocyanin (Ixor®) is more detected in patients with PTV < 500 ml, when Dmax reaches values lower or equal to 107%, but not exceeding 110% of the prescribed dose, and in patients undergoing adjuvant chemotherapy with anthracyclines and taxanes.

Published
2012
Full Text
View/download PDF

5. Artificial Intelligence-suggested Predictive Model of Survival in Patients Treated With Stereotactic Radiotherapy for Early Lung Cancer

Author

BORGHETTI, PAOLO, primary, COSTANTINO, GIANLUCA, additional, SANTORO, VALERIA, additional, MATAJ, ENEIDA, additional, SINGH, NAVDEEP, additional, VITALI, PAOLA, additional, GRECO, DIANA, additional, VOLPI, GIULIA, additional, SEPULCRI, MATTEO, additional, GUIDA, CESARE, additional, TOMASI, CESARE, additional, BUGLIONE, MICHELA, additional, and NARDONE, VALERIO, additional

Published
2024
Full Text
View/download PDF

9. Pros-IT CNR: an Italian prostate cancer monitoring project

Author

Noale, Marianna, Maggi, Stefania, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Maurizi Enrici, Riccardo, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Porreca, Angelo, Ricardi, Umberto, Tubaro, Andrea, Zagonel, Vittorina, Zattoni, Filiberto, Crepaldi, Gaetano, Crepaldi, Gaetano, Maggi, Stefania, Noale, Marianna, Porreca, Angelo, Artibani, Walter, Bassi, Pier Francesco, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Graziotti, Pierpaolo, Maurizi Enrici, Riccardo, Mirone, Vincenzo, Montironi, Rodolfo, Bertoni, Filippo, Gacci, Mauro, Magrini, Stefano Maria, Muto, Giovanni, Pecoraro, Stefano, Ricardi, Umberto, Tubaro, Andrea, Zagonel, Vittorina, Zattoni, Filiberto, Alitto, Anna Rita, Ambrosi, Enrica, Antonelli, Alessandro, Aristei, Cynthia, Barbieri, Michele, Bardari, Franco, Bardoscia, Lilia, Barra, Salvina, Bartoncini, Sara, Basso, Umberto, Becherini, Carlotta, Bellavita, Rita, Bergamaschi, Franco, Berlingheri, Stefania, Berruti, Alfredo, Borghesi, Marco, Bortolus, Roberto, Borzillo, Valentina, Bosetti, Davide, Bove, Giuseppe, Bove, Pierluigi, Brausi, Maurizio, Bruni, Alessio, Bruno, Giorgio, Brunocilla, Eugenio, Buffoli, Alberto, Buglione, Michela, Buttigliero, Consuelo, Cacciamani, Giovanni, Caldiroli, Michela, Cardo, Giuseppe, Carmignani, Giorgio, Carrieri, Giuseppe, Castelli, Emanuele, Castrezzati, Elisabetta, Catalano, Gianpiero, Cattarino, Susanna, Catucci, Francesco, Cavallini Francolini, Dario, Ceccarini, Ofelia, Celia, Antonio, Chiancone, Francesco, Chini, Tommaso, Cianci, Claudia, Cisternino, Antonio, Collura, Devis, Corbella, Franco, Corinti, Matteo, Corsi, Paolo, Cortese, Fiorenza, Corti, Luigi, de Nunzio, Cosimo, Cristiano, Olga, D’Angelillo, Rolando, Da Pozzo, Luigi, D’agostino, Daniele, D’Andrea, David, Dandrea, Matteo, De Angelis, Michele, De Cobelli, Ottavio, De Concilio, Bernardino, De Lisa, Antonello, De Luca, Stefano, De Stefani, Agostina, Deantoni, Chiara Lucrezia, Degli Esposti, Claudio, Destito, Anna, Detti, Beatrice, Di Muzio, Nadia, Di Stasio, Andrea, Di Stefano, Calogero, Di Trapani, Danilo, Difino, Giuseppe, Falivene, Sara, Farullo, Giuseppe, Fedelini, Paolo, Ferrari, Ilaria, Ferrau, Francesco, Ferro, Matteo, Fodor, Andrei, Fontana, Francesco, Francesca, Francesco, Giulio, Francolini, Frata, Paolo, Frezza, Giovanni, Gabriele, Pietro, Galeandro, Maria, Garibaldi, Elisabetta, Gennari, Pietro, Gentilucci, Alessandro, Giacobbe, Alessandro, Giussani, Laura, Giusti, Giuseppe, Gontero, Paolo, Guarneri, Alessia, Guida, Cesare, Gurioli, Alberto, Huqi, Dorijan, Imbimbo, Ciro, Ingrosso, Gianluca, Iotti, Cinzia, Italia, Corrado, La Mattina, Pierdaniele, Lamanna, Enza, Lastrucci, Luciana, Lazzari, Grazia, Liberale, Fabiola, Liguori, Giovanni, Lisi, Roberto, Lohr, Frank, Lombardo, Riccardo, Lovisolo, Jon, Ludovico, Giuseppe Mario, Macchione, Nicola, Maggio, Francesca, Malizia, Michele, Manasse, Gianluca, Mandoliti, Giovanni, Mantini, Giovanna, Marafioti, Luigi, Marciello, Luisa, Marconi, Alberto Mario, Martillotta, Antonietta, Marzano, Salvino, Masciullo, Stefano, Maso, Gloria, Massenzo, Adele, Mazzeo, Ercole, Mearini, Luigi, Medoro, Serena, Molè, Rosa, Monesi, Giorgio, Montanari, Emanuele, Montefiore, Franco, Montesi, Giampaolo, Morgia, Giuseppe, Moro, Gregorio, Muscas, Giorgio, Musio, Daniela, Muto, Paolo, Muzzonigro, Giovanni, Napodano, Giorgio, Negro, Carlo Luigi Augusto, Nidini, Mattia, Ntreta, Maria, Orsatti, Marco, Palazzolo, Carmela, Palumbo, Isabella, Parisi, Alessandro, Parma, Paolo, Pavan, Nicola, Pericolini, Martina, Pinto, Francesco, Pistone, Antonio, Pizzuti, Valerio, Platania, Angelo, Polli, Caterina, Pomara, Giorgio, Ponti, Elisabetta, Porcaro, Antonio Benito, Porpiglia, Francesco, Pugliese, Dario, Pycha, Armin, Raguso, Giuseppe, Rampini, Andrea, Randone, Donato Franco, Roscigno, Marco, Ruggieri, Maria Paola, Ruoppo, Giuseppe, Sanseverino, Roberto, Santacaterina, Anna, Santarsieri, Michele, Santoni, Riccardo, Scagliarini, Sarah, Scagliotti, Giorgio Vittorio, Scanzi, Mauro, Scarcia, Marcello, Schiavina, Riccardo, Sciarra, Alessandro, Sciorio, Carmine, Scolaro, Tindaro, Scuzzarella, Salvatore, Selvaggio, Oscar, Serao, Armando, Serni, Sergio, Signor, Marco Andrea, Silvani, Mauro, Silvano, Giovanni, Silvestris, Franco, Simeone, Claudio, Simone, Valeria, Spagnoletti, Girolamo, Spinelli, Matteo Giulio, Squillace, Luigi, Tombolini, Vincenzo, Toninelli, Mariastella, Triggiani, Luca, Trinchieri, Alberto, Trodella, Luca Eolo, Trodella, Lucio, Trombetta, Carlo, Tronnolone, Lidia, Tucci, Marcello, Urzì, Daniele, Valdagni, Riccardo, Valeriani, Maurizio, Vanoli, Maurizio, Vitali, Elisabetta, Zaramella, Stefano, Zeccolini, Guglielmo, Zini, Giampaolo, and the Pros-IT CNR study group

Published
2017
Full Text
View/download PDF

10. Diffusion-weighted imaging and apparent diffusion coefficient mapping of head and neck lymph node metastasis: a systematic review

Author

Belfiore, Maria Paola, primary, Nardone, Valerio, additional, D’Onofrio, Ida, additional, Salvia, Antonio Alessandro Helliot, additional, D’Ippolito, Emma, additional, Gallo, Luigi, additional, Caliendo, Valentina, additional, Gatta, Gianluca, additional, Fasano, Morena, additional, Grassi, Roberta, additional, Angrisani, Antonio, additional, Guida, Cesare, additional, Reginelli, Alfonso, additional, and Cappabianca, Salvatore, additional

Published
2022
Full Text
View/download PDF

12. Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery

Author

Nardone, Valerio, primary, Reginelli, Alfonso, additional, Grassi, Roberta, additional, Vacca, Giovanna, additional, Giacobbe, Giuliana, additional, Angrisani, Antonio, additional, Clemente, Alfredo, additional, Danti, Ginevra, additional, Correale, Pierpaolo, additional, Carbone, Salvatore Francesco, additional, Pirtoli, Luigi, additional, Bianchi, Lorenzo, additional, Vanzulli, Angelo, additional, Guida, Cesare, additional, Grassi, Roberto, additional, and Cappabianca, Salvatore, additional

Published
2022
Full Text
View/download PDF

13. Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy

Author

Fasano, Morena, primary, D’Onofrio, Ida, additional, Belfiore, Maria Paola, additional, Angrisani, Antonio, additional, Caliendo, Valentina, additional, Della Corte, Carminia Maria, additional, Pirozzi, Mario, additional, Facchini, Sergio, additional, Caterino, Marianna, additional, Guida, Cesare, additional, Nardone, Valerio, additional, Reginelli, Alfonso, additional, and Cappabianca, Salvatore, additional

Published
2022
Full Text
View/download PDF

18. Mood Disorder in Cancer Patients Undergoing Radiotherapy During the COVID-19 Outbreak

Author

Nardone, Valerio, primary, Reginelli, Alfonso, additional, Vinciguerra, Claudia, additional, Correale, Pierpaolo, additional, Calvanese, Maria Grazia, additional, Falivene, Sara, additional, Sangiovanni, Angelo, additional, Grassi, Roberta, additional, Di Biase, Angela, additional, Polifrone, Maria Angela, additional, Caraglia, Michele, additional, Cappabianca, Salvatore, additional, and Guida, Cesare, additional

Published
2021
Full Text
View/download PDF

20. Neck emphysema in a HNSCC cancer patient undergoing concurrent radiotherapy and cetuximab

Author

Nardone, Valerio, primary, Calvanese, Maria Grazia, additional, D’Onofrio, Ida, additional, Di Stasio, Mario, additional, Vitale, Claudio, additional, Silvestri, Antonia, additional, Daniele, Bruno, additional, Correale, Pierpaolo, additional, Fierro, Paolo, additional, Tortoriello, Giuseppe, additional, Reginelli, Alfonso, additional, Cappabianca, Salvatore, additional, and Guida, Cesare, additional

Published
2020
Full Text
View/download PDF

22. Radiomics predicts survival of patients with advanced non‑small cell lung cancer undergoing PD‑1 blockade using Nivolumab

Author

Nardone, Valerio, primary, Tini, Paolo, additional, Pastina, Pierpaolo, additional, Botta, Cirino, additional, Reginelli, Alfonso, additional, Carbone, Salvatore, additional, Giannicola, Rocco, additional, Calabrese, Grazia, additional, Tebala, Carmela, additional, Guida, Cesare, additional, Giudice, Aldo, additional, Barbieri, Vito, additional, Tassone, Pierfrancesco, additional, Tagliaferri, Pierosandro, additional, Cappabianca, Salvatore, additional, Capasso, Rosanna, additional, Luce, Amalia, additional, Caraglia, Michele, additional, Mazzei, Maria, additional, Pirtoli, Luigi, additional, and Correale, Pierpaolo, additional

Published
2019
Full Text
View/download PDF

27. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists

Author

Furlan, Carlo, primary, Arcangeli, Stefano, additional, Avanzo, Michele, additional, Mirri, Maria A., additional, Munoz, Fernando, additional, Giudici, Stefania, additional, Perrone, Antonio, additional, Amelio, Dante, additional, Tomio, Luigi, additional, Draghini, Loredana, additional, Deli, Aniko M., additional, Pavanato, Giovanni, additional, Giuliano, Francesca M., additional, Pontoriero, Antonio, additional, Ciammella, Patrizia, additional, Navarria, Pierina, additional, Iannalfi, Alberto, additional, Buglione, Michela, additional, Guida, Cesare, additional, Cammelli, Silvia, additional, Iorio, Vincenzo, additional, Cardinali, Massimo, additional, Genovesi, Domenico, additional, Barsacchi, Lucia, additional, Balducci, Mario, additional, Bagnoli, Rita, additional, Berti, Franco, additional, Montesi, Giampaolo, additional, Pasqualetti, Francesco, additional, Bonome, Paolo, additional, Santoni, Riccardo, additional, Doino, Daniela, additional, Schirru, Patrizia, additional, Pinzi, Valentina, additional, Borzillo, Valentina, additional, Ferrarese, Fabio, additional, Ferro, Marica, additional, Cicco, Luigi De, additional, Krengli, Marco, additional, Scoccianti, Silvia, additional, and Donato, Vittorio, additional

Published
2018
Full Text
View/download PDF

29. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.

Author

Nardone, Valerio, Tini, Paolo, Pastina, Pierpaolo, Botta, Cirino, Reginelli, Alfonso, Carbone, Salvatore Francesco, Giannicola, Rocco, Calabrese, Grazia, Tebala, Carmela, Guida, Cesare, Giudice, Aldo, Barbieri, Vito, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Cappabianca, Salvatore, Capasso, Rosanna, Luce, Amalia, Caraglia, Michele, Mazzei, Maria Antonietta, and Pirtoli, Luigi

Subjects
NON-small-cell lung carcinoma, IMMUNOTHERAPY, PROGRESSION-free survival, TRANSITIONAL cell carcinoma, RENAL cancer, URBAN hospitals
Abstract

Immune checkpoint blockade is an emerging anticancer strategy, and Nivolumab is a human mAb to PD-1 that is used in the treatment of a number of different malignancies, including non-small cell lung cancer (NSCLC), kidney cancer, urothelial carcinoma and melanoma. Although the use of Nivolumab prolongs survival in a number of patients, this treatment is hampered by high cost. Therefore, the identification of predictive markers of response to treatment in patients is required. In this context, PD-1/PDL1 blockade antitumor effects occur through the reactivation of a pre-existing immune response, and the efficacy of these effects is strictly associated with the presence of necrosis, hypoxia and inflammation at the tumour sites. It has been indicated that these events can be evaluated by specific assessments using a computed tomography (CT) texture analysis (TA) or radiomics. Therefore, a retrospective study was performed, which aimed to evaluate the potential use of this analysis in the identification of patients with NSCLC who may benefit from Nivolumab treatment. A retrospective analysis was performed of 59 patients with metastatic NSCLC who received Nivolumab treatment between January 2015 and July 2017 at Siena University Hospital (35 patients, training dataset), Catanzaro University Hospital and Reggio Calabria Grand Metropolitan Hospital, Italy (24 patients, validation dataset). Pre- and post-contrast CT sequences were used to contour the gross tumour volume (GTV) of the target lesions prior to Nivolumab treatment. The impact of variations on contouring was analysed using two delineations, which were performed on each patient, and the TA parameters were tested for reliability using the Intraclass Coefficient Correlation method (ICC). All analyses for the current study were performed using LifeX Software©. Imaging, clinical and pathological parameters were correlated with progression free survival and overall survival (OS) using Kaplan Meier analysis. An external validation testing was performed for the TA Score using the validation dataset. A total of 59 patients were included in the analysis of the present study. The reliability ICC analysis of 14 TA parameters indicated a highly reproducibility (ICC >0.70, single measure) in 12 (85%) pre- contrast and 13 (93%) post-contrast exams. A specific cut-off was detected for each of the following parameters: volume (score 1 >36 ml), histogram entropy (score 1 > 1.30), compacity (score 1 <3), gray level co-occurrence matrix (GLCM)-entropy (score 1 >1.80), GLCM-Dissimilarity (score 1 >5) and GLCM-Correlation (score 1<0.54). The global texture score allowed the classification of two subgroups of Low (Score 0–1; 36 patients; 61%) and High Risk patients (Score >1; 23 patients; 39%) that respectively, showed a median OS of 26 (mean +/- SD: 18 +/- 1.98 months; 95% CI 14–21 months) and 5 months (mean +/- SD: 6 +/- 0.99 months; 95% CI: 4–8 months; P=0.002). The current study indicated that TA parameters can identify patients that will benefit from PD-1 blockage by defining the radiological settings that are potentially suggestive of an active immune response. These results require further confirmation in prospective trials. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

30. Rolle des perilesionalen Ödems und des Tumorvolumens bei der Prognose von nicht-kleinzelligem Lungenkrebs (NSCLC) nach einer Radiochirurgie (SRS) von Hirnmetastasen.

Author

Nardone, Valerio, Nanni, Sara, Pastina, Pierpaolo, Vinciguerra, Claudia, Cerase, Alfonso, Correale, Pierpaolo, Guida, Cesare, Giordano, Antonio, Tini, Paolo, Reginelli, Alfonso, Cappabianca, Salvatore, and Pirtoli, Luigi

Abstract

Copyright of Strahlentherapie und Onkologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019
Full Text
View/download PDF

31. Pros-IT CNR: an Italian prostate cancer monitoring project

Author

Bassi, Pierfrancesco, Maggi, Ilaria Stefania, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Maurizi Enrici, Riccardo, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Porreca, Angelo, Ricardi, Umberto, Tubaro, Andrea, Zagonel, Vittorina, Zattoni, Filiberto, Crepaldi, Gaetano, Noale, Marianna, Alitto, Anna Rita, Ambrosi, Enrica, Antonelli, Alessandro, Aristei, Cynthia, Barbieri, Michele, Bardari, Franco, Bardoscia, Lilia, Barra, Salvina, Bartoncini, Sara, Basso, Umberto, Becherini, Carlotta, Bellavita, Rita, Bergamaschi, Franco, Berlingheri, Stefania, Berruti, Alfredo, Borghesi, Marco, Bortolus, Roberto, Borzillo, Valentina, Bosetti, Davide, Bove, Giuseppe, Bove, Pierluigi, Brausi, Maurizio, Bruni, Alessio, Baldari, Giorgio Bruno Cristiano, Brunocilla, Eugenio, Buffoli, Alberto, Buglione, Michela, Buttigliero, Consuelo, Cacciamani, Giovanni, Caldiroli, Michela, Cardo, Giuseppe, Carmignani, Giorgio, Carrieri, Giuseppe, Castelli, Emanuele, Castrezzati, Elisabetta, Catalano, Gianpiero, Cattarino, Susanna, Catucci, Francesco, Cavallini Francolini, Dario, Ceccarini, Ofelia, Celia, Antonio, Chiancone, Francesco, Chini, Tommaso, Cianci, Claudia, Cisternino, Antonio, Collura, Devi, Corbella, Franco, Corinti, Matteo, Corsi, Paolo, Cortese, Fiorenza, Corti, Luigi, de Nunzio, Cosimo, Cristiano, Olga, D'Angelillo, Rolando Maria, Da Pozzo, Luigi, D'Agostino, Daniele, D’Andrea, David, Dandrea, Matteo, De Angelis, Michele, De Cobelli, Ottavio, De Concilio, Bernardino, De Lisa, Antonello, De Luca, Stefano, De Stefani, Agostina, Deantoni, Chiara Lucrezia, Degli Esposti, Claudio, Destito, Anna, Detti, Beatrice, Di Muzio, Nadia, Di Stasio, Andrea, Di Stefano, Calogero, Di Trapani, Danilo, Difino, Giuseppe, Falivene, Sara, Farullo, Giuseppe, Fedelini, Paolo, Ferrari, Ilaria, Ferrau, Francesco, Ferro, Matteo, Fodor, Andrei, Fontana, Francesco, Francesca, Francesco, Giulio, Francolini, Frata, Paolo, Frezza, Giovanni, Gabriele, Pietro, Galeandro, Maria, Garibaldi, Ida Marina Elisabetta, Gennari, Pietro, Gentilucci, Alessandro, Giacobbe, Alessandro, Giussani, Laura, Giusti, Giuseppe, Gontero, Paolo, Guarneri, Alessia, Guida, Cesare, Gurioli, Alberto, Huqi, Dorijan, Imbimbo, Ciro, Ingrosso, Gianluca, Iotti, Cinzia, Italia, Corrado, La Mattina, Pierdaniele, Lamanna, Enza, Lastrucci, Luciana, Lazzari, Grazia, Liberale, Fabiola, Liguori, Giovanni, Lisi, Roberto, Lohr, Frank, Lombardo, Riccardo, Lovisolo, Jon, Ludovico, Giuseppe Mario, Macchione, Nicola, Maggio, Francesca, Malizia, Michele, Manasse, Gianluca, Mandoliti, Giovanni, Mantini, Giovanna, Marafioti, Luigi, Marciello, Luisa, Marconi, Alberto Mario, Martillotta, Antonietta, Marzano, Salvino, Masciullo, Stefano, Maso, Gloria, Massenzo, Adele, Mazzeo, Ercole, Mearini, Luigi, Medoro, Serena, Molè, Rosa, Monesi, Giorgio, Montanari, Emanuele, Montefiore, Franco, Montesi, Giampaolo, Morgia, Giuseppe, Moro, Gregorio, Muscas, Giorgio, Musio, Daniela, Muto, Paolo, Muzzonigro, Giovanni, Napodano, Giorgio, Negro, Carlo Luigi Augusto, Nidini, Mattia, Ntreta, Maria, Orsatti, Marco, Palazzolo, Carmela, Palumbo, Isabella, Parisi, Alessandro, Parma, Paolo, Pavan, Nicola, Pericolini, Martina, Pinto, Francesco, Pistone, Antonio, Pizzuti, Valerio, Platania, Angelo, Polli, Caterina, Pomara, Giorgio, Ponti, Elisabetta, Porcaro, Antonio Benito, Porpiglia, Francesco, Pugliese, Dario, Pycha, Armin, Raguso, Giuseppe, Rampini, Andrea, Randone, Donato Franco, Roscigno, Marco, Ruggieri, Maria Paola, Ruoppo, Giuseppe, Sanseverino, Roberto, Santacaterina, Anna, Santarsieri, Michele, Santoni, Riccardo, Scagliarini, Sarah, Scagliotti, Giorgio Vittorio, Scanzi, Mauro, Scarcia, Marcello, Schiavina, Riccardo, Sciarra, Alessandro, Sciorio, Carmine, Scolaro, Tindaro, Scuzzarella, Salvatore, Selvaggio, Oscar, Serao, Armando, Serni, Sergio, Signor, Marco Andrea, Silvani, Mauro, Silvano, Giovanni, Silvestris, Franco, Simeone, Claudio, Simone, Valeria, Spagnoletti, Girolamo, Spinelli, Matteo Giulio, Squillace, Luigi, Tombolini, Vincenzo, Toninelli, Mariastella, Triggiani, Luca, Trinchieri, Alberto, Trodella, Luca Eolo, Trodella, Lucio, Trombetta, Carlo, Tronnolone, Lidia, Tucci, Marcello, Urzì, Daniele, Valdagni, Riccardo, Valeriani, Maurizio, Vanoli, Maurizio, Vitali, Elisabetta, Zaramella, Stefano, Zeccolini, Guglielmo, Zini, Giampaolo, Noale, Marianna (ORCID:0000-0002-4313-8427), Maggi, Stefania, D’Angelillo, Rolando, D’agostino, Daniele, Mantini, Giovanna (ORCID:0000-0001-5303-4499), Bassi, Pierfrancesco, Maggi, Ilaria Stefania, Artibani, Walter, Bassi, Pier Francesco, Bertoni, Filippo, Bracarda, Sergio, Conti, Giario Natale, Corvò, Renzo, Gacci, Mauro, Graziotti, Pierpaolo, Magrini, Stefano Maria, Maurizi Enrici, Riccardo, Mirone, Vincenzo, Montironi, Rodolfo, Muto, Giovanni, Pecoraro, Stefano, Porreca, Angelo, Ricardi, Umberto, Tubaro, Andrea, Zagonel, Vittorina, Zattoni, Filiberto, Crepaldi, Gaetano, Noale, Marianna, Alitto, Anna Rita, Ambrosi, Enrica, Antonelli, Alessandro, Aristei, Cynthia, Barbieri, Michele, Bardari, Franco, Bardoscia, Lilia, Barra, Salvina, Bartoncini, Sara, Basso, Umberto, Becherini, Carlotta, Bellavita, Rita, Bergamaschi, Franco, Berlingheri, Stefania, Berruti, Alfredo, Borghesi, Marco, Bortolus, Roberto, Borzillo, Valentina, Bosetti, Davide, Bove, Giuseppe, Bove, Pierluigi, Brausi, Maurizio, Bruni, Alessio, Baldari, Giorgio Bruno Cristiano, Brunocilla, Eugenio, Buffoli, Alberto, Buglione, Michela, Buttigliero, Consuelo, Cacciamani, Giovanni, Caldiroli, Michela, Cardo, Giuseppe, Carmignani, Giorgio, Carrieri, Giuseppe, Castelli, Emanuele, Castrezzati, Elisabetta, Catalano, Gianpiero, Cattarino, Susanna, Catucci, Francesco, Cavallini Francolini, Dario, Ceccarini, Ofelia, Celia, Antonio, Chiancone, Francesco, Chini, Tommaso, Cianci, Claudia, Cisternino, Antonio, Collura, Devi, Corbella, Franco, Corinti, Matteo, Corsi, Paolo, Cortese, Fiorenza, Corti, Luigi, de Nunzio, Cosimo, Cristiano, Olga, D'Angelillo, Rolando Maria, Da Pozzo, Luigi, D'Agostino, Daniele, D’Andrea, David, Dandrea, Matteo, De Angelis, Michele, De Cobelli, Ottavio, De Concilio, Bernardino, De Lisa, Antonello, De Luca, Stefano, De Stefani, Agostina, Deantoni, Chiara Lucrezia, Degli Esposti, Claudio, Destito, Anna, Detti, Beatrice, Di Muzio, Nadia, Di Stasio, Andrea, Di Stefano, Calogero, Di Trapani, Danilo, Difino, Giuseppe, Falivene, Sara, Farullo, Giuseppe, Fedelini, Paolo, Ferrari, Ilaria, Ferrau, Francesco, Ferro, Matteo, Fodor, Andrei, Fontana, Francesco, Francesca, Francesco, Giulio, Francolini, Frata, Paolo, Frezza, Giovanni, Gabriele, Pietro, Galeandro, Maria, Garibaldi, Ida Marina Elisabetta, Gennari, Pietro, Gentilucci, Alessandro, Giacobbe, Alessandro, Giussani, Laura, Giusti, Giuseppe, Gontero, Paolo, Guarneri, Alessia, Guida, Cesare, Gurioli, Alberto, Huqi, Dorijan, Imbimbo, Ciro, Ingrosso, Gianluca, Iotti, Cinzia, Italia, Corrado, La Mattina, Pierdaniele, Lamanna, Enza, Lastrucci, Luciana, Lazzari, Grazia, Liberale, Fabiola, Liguori, Giovanni, Lisi, Roberto, Lohr, Frank, Lombardo, Riccardo, Lovisolo, Jon, Ludovico, Giuseppe Mario, Macchione, Nicola, Maggio, Francesca, Malizia, Michele, Manasse, Gianluca, Mandoliti, Giovanni, Mantini, Giovanna, Marafioti, Luigi, Marciello, Luisa, Marconi, Alberto Mario, Martillotta, Antonietta, Marzano, Salvino, Masciullo, Stefano, Maso, Gloria, Massenzo, Adele, Mazzeo, Ercole, Mearini, Luigi, Medoro, Serena, Molè, Rosa, Monesi, Giorgio, Montanari, Emanuele, Montefiore, Franco, Montesi, Giampaolo, Morgia, Giuseppe, Moro, Gregorio, Muscas, Giorgio, Musio, Daniela, Muto, Paolo, Muzzonigro, Giovanni, Napodano, Giorgio, Negro, Carlo Luigi Augusto, Nidini, Mattia, Ntreta, Maria, Orsatti, Marco, Palazzolo, Carmela, Palumbo, Isabella, Parisi, Alessandro, Parma, Paolo, Pavan, Nicola, Pericolini, Martina, Pinto, Francesco, Pistone, Antonio, Pizzuti, Valerio, Platania, Angelo, Polli, Caterina, Pomara, Giorgio, Ponti, Elisabetta, Porcaro, Antonio Benito, Porpiglia, Francesco, Pugliese, Dario, Pycha, Armin, Raguso, Giuseppe, Rampini, Andrea, Randone, Donato Franco, Roscigno, Marco, Ruggieri, Maria Paola, Ruoppo, Giuseppe, Sanseverino, Roberto, Santacaterina, Anna, Santarsieri, Michele, Santoni, Riccardo, Scagliarini, Sarah, Scagliotti, Giorgio Vittorio, Scanzi, Mauro, Scarcia, Marcello, Schiavina, Riccardo, Sciarra, Alessandro, Sciorio, Carmine, Scolaro, Tindaro, Scuzzarella, Salvatore, Selvaggio, Oscar, Serao, Armando, Serni, Sergio, Signor, Marco Andrea, Silvani, Mauro, Silvano, Giovanni, Silvestris, Franco, Simeone, Claudio, Simone, Valeria, Spagnoletti, Girolamo, Spinelli, Matteo Giulio, Squillace, Luigi, Tombolini, Vincenzo, Toninelli, Mariastella, Triggiani, Luca, Trinchieri, Alberto, Trodella, Luca Eolo, Trodella, Lucio, Trombetta, Carlo, Tronnolone, Lidia, Tucci, Marcello, Urzì, Daniele, Valdagni, Riccardo, Valeriani, Maurizio, Vanoli, Maurizio, Vitali, Elisabetta, Zaramella, Stefano, Zeccolini, Guglielmo, Zini, Giampaolo, Noale, Marianna (ORCID:0000-0002-4313-8427), Maggi, Stefania, D’Angelillo, Rolando, D’agostino, Daniele, and Mantini, Giovanna (ORCID:0000-0001-5303-4499)

Abstract

Aims: The Pros-IT CNR project aims to monitor a sample of Italian males ≥18 years of age who have been diagnosed in the participating centers with incident prostate cancer, by analyzing their clinical features, treatment protocols and outcome results in relation to quality of life. Methods: Pros-IT CNR is an observational, prospective, multicenter study. The National Research Council (CNR), Neuroscience Institute, Aging Branch (Padua) is the promoting center. Ninety-seven Italian centers located throughout Italy were involved. The field study began in September 1, 2014. Subjects eligible were diagnosed with biopsy-verified prostate cancer, naà ̄ve. A sample size of 1500 patients was contemplated. A baseline assessment including anamnestic data, clinical history, risk factors, the initial diagnosis, cancer staging information and quality of life (Italian UCLA Prostate Cancer Index; SF-12 Scale) was completed. Six months after the initial diagnosis, a second assessment evaluating the patient’s health status, the treatment carried out, and the quality of life will be made. A third assessment, evaluating the treatment follow-up and the quality of life, will be made 12 months after the initial diagnosis. The 4th, 5th, 6th and 7th assessments, similar to the third, will be completed 24, 36, 48 and 60 months after the initial diagnosis, respectively, and will include also a Food Frequency Questionnaire and the Physical Activity Scale for the Elderly. Discussion: The study will provide information on patients’ quality of life and its variations over time in relation to the treatments received for the prostate cancer.

Published
2017

32. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists

Author

Furlan, Carlo, Arcangeli, Stefano, Avanzo, Michele, Mirri, Maria Alessandra, Munoz, Fernando, Giudici, Stefania, Perrone, Antonio, Amelio, Dante, Tomio, Luigi, Draghini, Loredana, Deli, Aniko M, Pavanato, Giovanni, Giugliano, Francesca M, Pontoriero, Antonio, Ciammella, Patrizia, Navarria, Pierina, Iannalfi, Alberto, Buglione, Michela, Guida, Cesare, Cammelli, Silvia, Iorio, Vincenzo, Cardinali, Massimo, Genovesi, Domenico, Barsacchi, Lucia, Balducci, Mario, Bagnoli, Rita, Berti, Franco, Montesi, Giampaolo, Pasqualetti, Francesco, Bonome, Paolo, Santoni, Riccardo, Doino, Daniela, Schirru, Patrizia, Pinzi, Valentina, Borzillo, Valentina, Ferrarese, Fabio, Ferro, Marica, De Cicco, Luigi, Krengli, Marco, Scoccianti, Silvia, Donato, Vittorio, Mirri, Maria A, Balducci, Mario (ORCID:0000-0003-0398-9726), Furlan, Carlo, Arcangeli, Stefano, Avanzo, Michele, Mirri, Maria Alessandra, Munoz, Fernando, Giudici, Stefania, Perrone, Antonio, Amelio, Dante, Tomio, Luigi, Draghini, Loredana, Deli, Aniko M, Pavanato, Giovanni, Giugliano, Francesca M, Pontoriero, Antonio, Ciammella, Patrizia, Navarria, Pierina, Iannalfi, Alberto, Buglione, Michela, Guida, Cesare, Cammelli, Silvia, Iorio, Vincenzo, Cardinali, Massimo, Genovesi, Domenico, Barsacchi, Lucia, Balducci, Mario, Bagnoli, Rita, Berti, Franco, Montesi, Giampaolo, Pasqualetti, Francesco, Bonome, Paolo, Santoni, Riccardo, Doino, Daniela, Schirru, Patrizia, Pinzi, Valentina, Borzillo, Valentina, Ferrarese, Fabio, Ferro, Marica, De Cicco, Luigi, Krengli, Marco, Scoccianti, Silvia, Donato, Vittorio, Mirri, Maria A, and Balducci, Mario (ORCID:0000-0003-0398-9726)

Abstract

PURPOSE: To assess the contribution of Italian radiation oncologists in the current management of recurrent high-grade gliomas (HGG), focusing on a reirradiation (reRT) approach. METHODS: In 2015, the Reirradiation and the Central Nervous System Study Groups on behalf of the Italian Association of Radiation Oncology (AIRO) proposed a survey. All Italian radiation oncologists were individually invited to complete an online questionnaire regarding their clinical management of recurrent HGG, focusing on a reRT approach. RESULTS: A total of 37 of 210 questionnaires were returned (18% of all centers): 16 (43%) from nonacademic hospitals, 14 (38%) from academic hospitals, 5 (13%) from private institutions, and 2 (6%) from hadron therapy centers. The majority of responding centers (59%) treated ≤5 cases per year. Performance status at the time of recurrence, along with a target diameter <5 cm and an interval from primary radiation ≥6 months, were the prevalent predictive factors considered for reRT. Sixty percent of reirradiated patients had already received a salvage therapy, either chemotherapy (40%) or reoperation (20%). The most common approach for reRT was fractionated stereotactic radiotherapy to a mean (photon) dose of 41.6 Gy. CONCLUSIONS: Although there were wide variations in the clinical practice of reRT across the 37 centers, the core activities were reasonably consistent. These findings provide a basis for encouraging a national collaborative study to develop, implement, and monitor the use of reRT in this challenging clinical setting.

Published
2017

35. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer

Author

C. Sacco, Paola, Maione, Paolo, Guida, Cesare, and Gridelli, Cesare

Abstract

Lung cancer is the main reason of cancer death worldwide. About 30% of non-small-cell lung cancer (NSCLC) cases are diagnosed with locally advanced disease (stage III). This is a mixed population including patients who have far more extensive and bulky disease than others. Management of these patients continue to be a challenge; frequently, patients have both local recurrence and distant metastases in this stage and the prognosis is very poor with a 5-year overall survival estimated between 3% and 7% for inoperable disease. The standard treatment for these patients is concurrent chemo-radiotherapy (CRT) improving survival when compared to sequential combination as shown in several metanalysis. Recently, immune-therapies, including checkpoint inhibitor, such as monoclonal antibodies against programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1), have shown to enhance survival compared to chemotherapy in patients with advanced NSCLC. The integration of radiotherapy with immunotherapy is a conceptually promising strategy and several preclinical experiments have further developed the rationale for combining them. Radiotherapy has the capacity to overcome a lot of tumor immune escape mechanisms through the liberation of immunogenic private antigens showing a better local control and augmenting the immune response of systemic agents. This manuscript discusses the potential clinical interest for the combination of radiation and immunotherapy in locally advanced NSCLC.

Published
2017
Full Text
View/download PDF

39. Il Gerone

Author

Jenofonte, Guida, Cesare, Jenofonte, and Guida, Cesare

Abstract

Data tomada de verso de portada.

Published
1923

40. Diffusion-weighted imaging and apparent diffusion coefficient mapping of head and neck lymph node metastasis: a systematic review

Author

Maria Paola Belfiore, Valerio Nardone, Ida D’Onofrio, Antonio Alessandro Helliot Salvia, Emma D’Ippolito, Luigi Gallo, Valentina Caliendo, Gianluca Gatta, Morena Fasano, Roberta Grassi, Antonio Angrisani, Cesare Guida, Alfonso Reginelli, Salvatore Cappabianca, Belfiore, Maria Paola, Nardone, Valerio, D’Onofrio, Ida, Alessandro Helliot Salvia, Antonio, D’Ippolito, Emma, Gallo, Luigi, Caliendo, Valentina, Gatta, Gianluca, Fasano, Morena, Grassi, Roberta, Angrisani, Antonio, Guida, Cesare, Reginelli, Alfonso, and Cappabianca, Salvatore

Subjects
head and neck squamous cell cancer, magnetic resonance imaging, head and neck cancer, Diffusion-weighted imaging, lymph node
Abstract

Aim: Head and neck squamous cell cancer (HNSCC) is the ninth most common tumor worldwide. Neck lymph node (LN) status is the major indicator of prognosis in all head and neck cancers, and the early detection of LN involvement is crucial in terms of therapy and prognosis. Diffusion-weighted imaging (DWI) is a non-invasive imaging technique used in magnetic resonance imaging (MRI) to characterize tissues based on the displacement motion of water molecules. This review aims to provide an overview of the current literature concerning quantitative diffusion imaging for LN staging in patients with HNSCC. Methods: This systematic review performed a literature search on the PubMed database (https://pubmed.ncbi.nlm.nih.gov/) for all relevant, peer-reviewed literature on the subject following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) criteria, using the keywords: DWI, MRI, head and neck, staging, lymph node. Results: After excluding reviews, meta-analyses, case reports, and bibliometric studies, 18 relevant papers out of the 567 retrieved were selected for analysis. Conclusions: DWI improves the diagnosis, treatment planning, treatment response evaluation, and overall management of patients affected by HNSCC. More robust data to clarify the role of apparent diffusion coefficient (ADC) and DWI parameters are needed to develop models for prognosis and prediction in HNSCC cancer using MRI.

Published
2022
Full Text
View/download PDF

41. Lumbosacral Plexopathy in Pelvic Radiotherapy: An Association not to be Neglected; A Systematic Review

Author

Claudia Vinciguerra, Francesco Sicurelli, Salvatore Cappabianca, Valerio Nardone, Cesare Guida, Vinciguerra, Claudia, Nardone, Valerio, Sicurelli, Francesco, Guida, Cesare, and Cappabianca, Salvatore

Subjects
030506 rehabilitation, medicine.medical_specialty, business.industry, General Neuroscience, medicine.medical_treatment, Context (language use), Disease, Radiation therapy, 03 medical and health sciences, Psychiatry and Mental health, Lumbosacral plexus, 0302 clinical medicine, Organ sparing, Web of knowledge, medicine, Medical physics, Neurology (clinical), 0305 other medical science, business, Pelvic radiotherapy, 030217 neurology & neurosurgery, Lumbosacral plexopathy
Abstract

Context: Radiation-induced lumbosacral plexopathy is still under-recognized although its symptomatology can really lower the quality of life and impair self-sufficient functions of patients often cured of cancer. Objectives: This review aimed to depict radiation-induced lumbosacral plexopathy through a systematic review of the available literature and discuss various aspects of the clinical management of this pathology. Data Sources: We searched for all English medical papers registered in Web of Knowledge, PubMed, Google Scholar, and ScienceDirect from January 1990 to November 2018. Study Selection: From among all articles concerning radiotherapy and lumbosacral plexopathy, we included papers that dealt with human samples and excluded non-human samples and case reports. Results: Out of 1,312 articles, we selected 42 articles of which 21 met the eligibility criteria and were included in the present analysis. Five papers were general reviews, three focused on the diagnosis of disease, three analyzed the role of different therapies, and the remaining 10 articles concerned the methodology of radiation therapy. Conclusion: In the next future, we must analyze the dosimetry parameters and the clinical parameters, with appropriate follow-up times, thus providing sufficient data to use for developing organ sparing strategies tailored to individual patients. Therefore, we can reduce this type of side effects that have a huge impact on the quality of life of patients.

Published
2019
Full Text
View/download PDF

42. The role of radiation therapy and systemic therapies in elderly with breast cancer

Author

Sara Falivene, Cesare Guida, Valerio Nardone, Francesca Maria Giugliano, Matteo Muto, Pasqualina Giordano, Bruno Daniele, Marcella Gaetano, Nardone, Valerio, Falivene, Sara, Giugliano, Francesca Maria, Gaetano, Marcella, Giordano, Pasqualina, Muto, Matteo, Daniele, Bruno, and Guida, Cesare

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Review Article, Lapatinib, adjuvant therapie, radiation therapy (RT), Breast cancer, Elderly, breast cancer, Atezolizumab, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Triple-negative breast cancer, novel drug, novel drugs, business.industry, medicine.disease, Clinical trial, Radiation therapy, Regimen, Pertuzumab, adjuvant therapies, business, medicine.drug
Abstract

The focus of this review deals with the management of elderly patients with early stage breast cancer, discussing the role of systemic therapies [endocrine therapy (ET), chemotherapy, novel agents] and radiation therapy (RT). Several studies have evaluated in elderly low risk patients the possibility of omitting the RT but, at the same time, higher locoregional relapse (LR) rates without significant impact on overall survival (OS) were observed in all studies when RT was excluded. Technological improvements [intensity-modulated RT (IMRT), volumetric modulated arc therapy (VMAT), high dose brachy therapy (HDBT)] are very useful in order to reduce cosmetic outcome and improve quality of life of frail patients. The optimal sequence of ET, concomitant or sequential to RT, is currently under investigation, and specifically in the elderly it is questioned the possible choice of prolonged therapy after standard 5 years. Data regarding chemotherapy suggesting no benefit of OS in endocrine responsive diseases, whereas endocrine non-responsive breast cancer still showed a better outcome. Cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimen is recognized as the standard protocol, although age-dependent increase in therapy related mortality was reported. Neoadjuvant chemotherapy in elderly showed a lower ratio of pathological complete response in comparison to younger patients, but triple negative breast cancer patients showed a good prognosis regarding OS, comparable to younger patients. The risk of cardiotoxicity seems to increase with age, so the use trastuzumab in this setting is much debated. Currently, other anti-HER2 agents (pertuzumab, lapatinib) are used in neoadjuvant setting, but the data on elderly are still premature. Novel molecules are rapidly changing the clinical management of breast cancer patients but are tested especially in locally advanced and metastatic setting. Among these, particularly interesting are inhibitors of CDK4 and 6, alpelisib (PI3K enzymes mutations), immune checkpoint (PD1, PDL1, CTLA4) inhibitors, atezolizumab. Elderly patients are under-represented in clinical trials, although ageing can be frequently correlated with a decrease in the effectiveness of the immune system. For elderly women, treatment decisions should be individually decided, taking into account the geriatric assessment and limited life expectancy and tumor characteristics.

Published
2019

43. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists

Author

Furlan, C, Arcangeli, S, Avanzo, M, Mirri, MA, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, DELI, ANIKO' MARIA, Pavanato, G, Giuliano, FM, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, Donato, V, PINZI, VALENTINA, Furlan, Carlo, Arcangeli, Stefano, Avanzo, Michele, Mirri, Maria A, Munoz, Fernando, Giudici, Stefania, Perrone, Antonio, Amelio, Dante, Tomio, Luigi, Draghini, Loredana, Deli, Aniko M, Pavanato, Giovanni, Giugliano, Francesca M, Pontoriero, Antonio, Ciammella, Patrizia, Navarria, Pierina, Iannalfi, Alberto, Buglione, Michela, Guida, Cesare, Cammelli, Silvia, Iorio, Vincenzo, Cardinali, Massimo, Genovesi, Domenico, Barsacchi, Lucia, Balducci, Mario, Bagnoli, Rita, Berti, Franco, Montesi, Giampaolo, Pasqualetti, Francesco, Bonome, Paolo, Santoni, Riccardo, Doino, Daniela, Schirru, Patrizia, Pinzi, Valentina, Borzillo, Valentina, Ferrarese, Fabio, Ferro, Marica, De Cicco, Luigi, Krengli, Marco, Scoccianti, Silvia, Donato, Vittorio, Furlan, C, Arcangeli, S, Avanzo, M, Mirri, M, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, Deli, A, Pavanato, G, Giuliano, F, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, and Donato, V

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, gliomas (HGG), Radiosurgery, 030218 nuclear medicine & medical imaging, Re-Irradiation, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Glioma, Surveys and Questionnaires, Reirradiation, gliomas (HGG), Medicine, Humans, dose, glioblastoma, glioma, IMRT, radiosurgery, reirradiation, IMRT, Reirradiation, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Salvage Therapy, RECURRENT HIGH GRADE GLIOMA, business.industry, Dose, Glioblastoma, Radiation Oncologists, General Medicine, medicine.disease, Combined Modality Therapy, SURVEY, Current management, Italy, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
Abstract

Purpose: To assess the contribution of Italian radiation oncologists in the current management of recurrent high-grade gliomas (HGG), focusing on a reirradiation (reRT) approach. Methods: In 2015, the Reirradiation and the Central Nervous System Study Groups on behalf of the Italian Association of Radiation Oncology (AIRO) proposed a survey. All Italian radiation oncologists were individually invited to complete an online questionnaire regarding their clinical management of recurrent HGG, focusing on a reRT approach. Results: A total of 37 of 210 questionnaires were returned (18% of all centers): 16 (43%) from nonacademic hospitals, 14 (38%) from academic hospitals, 5 (13%) from private institutions, and 2 (6%) from hadron therapy centers. The majority of responding centers (59%) treated ≤5 cases per year. Performance status at the time of recurrence, along with a target diameter Conclusions: Although there were wide variations in the clinical practice of reRT across the 37 centers, the core activities were reasonably consistent. These findings provide a basis for encouraging a national collaborative study to develop, implement, and monitor the use of reRT in this challenging clinical setting.

Published
2017

44. Treatment Volume, Dose Prescription and Delivery Techniques for Dose-intensification in Rectal Cancer: A National Survey.

Author

Caravatta L, Lupattelli M, Mantello G, Gambacorta MA, Chiloiro G, DI Tommaso M, Rosa C, Gasparini L, Morganti AG, Picardi V, Niespolo RM, Osti MF, Montrone S, Simoni N, Boso C, Facchin F, Deidda MA, Piva C, Guida C, Ziccarelli L, Munoz F, Ivaldi GB, Marchetti V, Franzone P, Spatola C, Franco P, Donato V, and Genovesi D

Subjects
Female, Humans, Italy epidemiology, Lymphatic Metastasis, Magnetic Resonance Imaging, Male, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Radiotherapy Dosage, Radiotherapy, Image-Guided adverse effects, Radiotherapy, Image-Guided methods, Radiotherapy, Image-Guided statistics & numerical data, Rectal Neoplasms diagnosis, Rectal Neoplasms mortality, Rectal Neoplasms pathology, Surveys and Questionnaires, Survival Analysis, Tumor Burden radiation effects, Practice Patterns, Physicians' statistics & numerical data, Radiotherapy Planning, Computer-Assisted adverse effects, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy Planning, Computer-Assisted statistics & numerical data, Radiotherapy, Intensity-Modulated adverse effects, Radiotherapy, Intensity-Modulated methods, Radiotherapy, Intensity-Modulated statistics & numerical data, Rectal Neoplasms radiotherapy, Tumor Burden physiology
Abstract

Background/aim: The aim of the study was to investigate boost volume definition, doses, and delivery techniques for rectal cancer dose intensification., Patients and Methods: An online survey was made on 25 items (characteristics, simulation, imaging, volumes, doses, planning and treatment)., Results: Thirty-eight radiation oncologists joined the study. Twenty-one delivered long-course radiotherapy with dose intensification. Boost volume was delineated on diagnostic magnetic resonance imaging (MRI) in 18 centres (85.7%), and computed tomography (CT) and/or positron emission tomography-CT in 9 (42.8%); 16 centres (76.2%) performed co-registration with CT-simulation. Boost dose was delivered on gross tumor volume in 10 centres (47.6%) and on clinical target volume in 11 (52.4%). The most common total dose was 54-55 Gy (71.4%), with moderate hypofractionation (85.7%). Intensity-modulated radiotherapy (IMRT) was used in all centres, with simultaneous integrated boost in 17 (80.8%) and image-guidance in 18 (85.7%)., Conclusion: A high quality of treatment using dose escalation can be inferred by widespread multidisciplinary discussion, MRI-based treatment volume delineation, and radiation delivery relying on IMRT with accurate image-guided radiation therapy protocols., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2021
Full Text
View/download PDF

45. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.

Author

Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P, Aloj L, De Martinis F, Comella P, Parisi V, and Lastoria S

Subjects
Adenocarcinoma diagnosis, Adenocarcinoma diagnostic imaging, Adenocarcinoma drug therapy, Adenocarcinoma radiotherapy, Adult, Aged, Antineoplastic Agents pharmacology, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Prognosis, ROC Curve, Rectal Neoplasms diagnosis, Rectal Neoplasms diagnostic imaging, Treatment Outcome, Fluorodeoxyglucose F18, Positron-Emission Tomography methods, Rectal Neoplasms drug therapy, Rectal Neoplasms radiotherapy
Abstract

Unlabelled: 18F-FDG PET is a useful tool for assessing the effects of chemo- or radiotherapy. The aim of this study was to correlate the change in tumor 18F-FDG standardized uptake value (SUV) during and after preoperative radiochemotherapy, with the pathologic response achieved in locally advanced rectal cancer (LARC) patients., Methods: Thirty-three patients with LARC underwent total mesorectal excision after preoperative treatment, including 3 cycles of oxaliplatin, raltitrexed, 5-fluorouracil, and folinic acid during pelvic radiotherapy (45 Gy). Staging procedures included endoscopic ultrasound, MRI, and CT. 18F-FDG PET scans were performed at baseline and 12 d after starting radiochemotherapy (intermediate) in all patients. Seventeen patients also had a presurgical scan. For each scan, mean and maximum SUVs were measured. The percentages of SUV decrease from baseline to intermediate (early change) and to presurgical scan (overall change) were assessed and correlated with pathologic response classified as tumor regression grade (TRG)., Results: Eighteen tumors (55%) showed complete (TRG1) or subtotal regression (TRG2) and were classified as responders, whereas 15 cases (45%; TRG3 or TRG4) were considered nonresponders. The early median decrease of tumor SUV significantly differed between responders (-62%; range, -44% to -100%) and nonresponders (-22%; range, -2% to -48%). A significant correlation was also found between TRGs and early SUV changes (P < 0.0001). Responders were identified correctly by an early decrease of the mean SUV of > or =52%., Conclusion: This study shows that early 18F-FDG PET can predict pathologic response to preoperative treatment. These findings support the usefulness of (18)F-FDG PET during the management with radiochemotherapy of LARC patients.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results